1. Home
  2. BLTE vs RDY Comparison

BLTE vs RDY Comparison

Compare BLTE & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BLTE
  • RDY
  • Stock Information
  • Founded
  • BLTE 2018
  • RDY 1984
  • Country
  • BLTE United States
  • RDY India
  • Employees
  • BLTE N/A
  • RDY N/A
  • Industry
  • BLTE Biotechnology: Pharmaceutical Preparations
  • RDY Biotechnology: Pharmaceutical Preparations
  • Sector
  • BLTE Health Care
  • RDY Health Care
  • Exchange
  • BLTE Nasdaq
  • RDY Nasdaq
  • Market Cap
  • BLTE 2.1B
  • RDY 2.1B
  • IPO Year
  • BLTE 2022
  • RDY N/A
  • Fundamental
  • Price
  • BLTE $56.40
  • RDY $13.67
  • Analyst Decision
  • BLTE Strong Buy
  • RDY Buy
  • Analyst Count
  • BLTE 4
  • RDY 1
  • Target Price
  • BLTE $96.67
  • RDY $17.00
  • AVG Volume (30 Days)
  • BLTE 37.7K
  • RDY 2.9M
  • Earning Date
  • BLTE 05-12-2025
  • RDY 05-06-2025
  • Dividend Yield
  • BLTE N/A
  • RDY 3.50%
  • EPS Growth
  • BLTE N/A
  • RDY 2.68
  • EPS
  • BLTE N/A
  • RDY 0.75
  • Revenue
  • BLTE N/A
  • RDY $3,637,607,642.00
  • Revenue This Year
  • BLTE N/A
  • RDY $17.23
  • Revenue Next Year
  • BLTE N/A
  • RDY $9.19
  • P/E Ratio
  • BLTE N/A
  • RDY $18.10
  • Revenue Growth
  • BLTE N/A
  • RDY 14.74
  • 52 Week Low
  • BLTE $32.25
  • RDY $12.26
  • 52 Week High
  • BLTE $86.53
  • RDY $16.89
  • Technical
  • Relative Strength Index (RSI)
  • BLTE 39.21
  • RDY 59.54
  • Support Level
  • BLTE $49.00
  • RDY $13.27
  • Resistance Level
  • BLTE $60.21
  • RDY $13.04
  • Average True Range (ATR)
  • BLTE 3.55
  • RDY 0.34
  • MACD
  • BLTE -0.57
  • RDY 0.09
  • Stochastic Oscillator
  • BLTE 41.67
  • RDY 95.92

About BLTE Belite Bio Inc

Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.

About RDY Dr. Reddy's Laboratories Ltd

Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.

Share on Social Networks: